The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
Open accessAbstract
Background Several agents provide treatment for established rheumatoid arthritis (RA), but a crucial therapeutic goal is to delay/prevent progression of undifferentiated arthritis (UA) or very early RA. Objective To determine the impact of T-cell costimulation modulation in patients with UA or very early RA. Methods In this double-blind, phase II, placebocontrolled, 2-year study, anti-cyclic citrullinated peptide (CCP)2-positive patients with UA (not fulfilling the ACR criteria for RA) and clinical synovitis of two or more joints were randomised to abatacept (∼10 mg/kg) or placebo for 6 months; the study drug was then terminated. The primary end point was development of RA (by ACR criteria) at year 1. Patients were monitored by radiography, MRI, CCP2, rheumatoid factor and 28 joint count Disease Activity Score (DAS28) over 2 years. Results At year 1, 12/26 (46%) abatacept-treated versus 16/24 (67%) placebo-treated patients developed RA (difference (95% CI) −20.5% (−47.4% to 7.8%)). Adjusted mean changes from baseline to year 1 in Genant-modified Sharp radiographic scores for abatacepttreated versus placebo-treated patients, respectively, were 0 versus 1.1 for total score, and 0 versus 0.9 for erosion score. Mean changes from baseline to year 1 in MRI erosion, osteitis and synovitis scores were 0, 0.2 and 0.2, respectively, versus 5.0, 6.7 and 2.3 in the abatacept versus placebo groups. Safety was comparable between groups; serious adverse events occurred in one patient (3.6%) in each group. Conclusion Abatacept delayed progression of UA/very early RA in some patients. An impact on radiographic and MRI inhibition was seen, which was maintained for 6 months after treatment stopped. This suggests that it is possible to alter the progression of RA by modulating T-cell responses at a very early stage of disease. Trial registration number NCT00124449.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Goekoop‐Ruiterman, Y. P. M., De Vries‐Bouwstra, J. K., Allaart, C. F., Van Zeben, D., Kerstens, P. J. S. M., Hazes, J. M. W., Zwinderman, A. H., Ronday, H. K., Han, K. H., Westedt, M. L., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21405 · Cited by 1,460
Grigor, C., Capell, H., Stirling, A., McMahon, A. D., Lock, P., Vallance, R., Porter, D., & Kincaid, W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16676-2 · Cited by 1,435
Rudwaleit, M., Landewé, R., van der Heijde, D., Listing, J., Brandt, J., Braun, J., Burgos-Vargas, R., Collantes-Estevez, E., Davis, J., Dijkmans, B., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.108217 · Cited by 941
Self-citationWells, G., Becker, J.-C., Teng, J., Dougados, M., Schiff, M., Smolen, J., Aletaha, D., & van Riel, P. L. C. M. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.084459 · Cited by 878
Self-citationEmery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., Singh, A., Pedersen, R. D., Koenig, A. S., & Freundlich, B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61000-4 · Cited by 821
Self-citationØstergaard, M., PETERFY, C. G., Conaghan, P. G., McQueen, F. M., Bird, P., Ejbjerg, B., Shnier, R., O’Connor, P., Klarlund, M., Emery, P., et al. (2003) · PubMed · Cited by 700
Self-citationRHEUMATOID ARTHRITIS: A DISEASE OF T-LYMPHOCYTE/MACROPHAGE IMMUNOREGULATION
Janossy, G., Duke, O., Poulter, L. W., Panayi, G., Bofill, M., & Goldstein, G. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91107-7 · Cited by 655
Huizinga, T. W. J., Amos, C. I., van der Helm‐van Mil, A. H. M., Chen, W., van Gaalen, F. A., Jawaheer, D., Schreuder, G. M. T., Wener, M., Breedveld, F. C., Ahmad, N., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21385 · Cited by 593
Raza, K., Falciani, F., Curnow, S. J., Ross, E. J., Lee, C.-Y., Akbar, A. N., Lord, J. M., Gordon, C., Buckley, C. D., & Salmon, M. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1733 · Cited by 515
Cited by
Treating rheumatoid arthritis to target: recommendations of an international task force
Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123919 · Cited by 2,100
Self-citationDi Matteo, A., Bathon, J. M., & Emery, P. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01525-8 · Cited by 849
Self-citationLopez-Olivo, M. A., Tayar, J. H., Martinez-Lopez, J. A., Pollono, E. N., Cueto, J. P., Gonzales-Crespo, M. R., Fulton, S., & Suarez-Almazor, M. E. (2012) · JAMA · doi:10.1001/2012.jama.10857 · Cited by 295
Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic?
de Rooy, D. P. C., van der Linden, M. P. M., Knevel, R., Huizinga, T. W. J., & van der Helm-van Mil, A. H. M. (2011) · Rheumatology · doi:10.1093/rheumatology/keq230 · Cited by 295
Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon‐Campos, J. A., Porawska, W., Box, J., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30463 · Cited by 196
Self-citation
Metadata
- Authors
- Emery, P., Durez, P., Dougados, M., Legerton, C. W., Becker, J.-C., Vratsanos, G., Genant, H. K., Peterfy, C., Mitra, P., Overfield, S., Qi, K., & Westhovens, R.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 69
- Issue
- 3
- Pages
- 510-516
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2128713459
- Cited by
- 255
- References
- 40
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). https://app.cochat.ai/papers/10.1136/ard.2009.119016
- The paper
- Emery, P., Durez, P., Dougados, M., Legerton, C. W., Becker, J.-C., Vratsanos, G., Genant, H. K., Peterfy, C., Mitra, P., Overfield, S., Qi, K., & Westhovens, R. (2010). Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard.2009.119016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
